{
  "id": 146,
  "text": "The palliative care specialist should be actively involved.Palliative taxane/platinum combination chemotherapy with/without bevacizumab is the preferred option.There is currently no standard second-line chemotherapy, and such patients should be considered for clinical trials.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: The palliative care specialist should be actively involved.Palliative taxane/platinum combination chemotherapy with/without bevacizumab is the preferred option.There is currently no standard second-line chemotherapy, and such patients should be considered for clinical trials.\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "在宫颈癌患者的一线化疗失败后，选择适当的治疗方案对缓解症状和延长生存时间非常重要。首先，建议积极加入缓和医疗团队，以提供全方位的支持。药物治疗方面，含有紫杉醇和铂类药物组合的化疗，可以考虑与或不与贝伐单抗（bevacizumab）联合使用，这是较为推荐的方案。\n\n目前，没有统一的标准二线化疗方案，因此对于这些患者来说，参与临床试验是值得考虑的选择。这可以为他们提供最新的治疗机会，并可能带来更好的临床结果。\n\n同时，针对个体情况调整治疗方案，并结合缓和疗法，可以帮助患者更好地管理疼痛及其他症状，从而提高生活质量。患者及其家属应与医生密切沟通，共同制定合适的治疗计划。",
  "query": "如果宫颈癌患者在一线化疗失败后，应如何选择治疗方案来缓解症状和延长生存时间？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 如果宫颈癌患者在一线化疗失败后，应如何选择治疗方案来缓解症状和延长生存时间？\n\n<reference text>: The palliative care specialist should be actively involved.Palliative taxane/platinum combination chemotherapy with/without bevacizumab is the preferred option.There is currently no standard second-line chemotherapy, and such patients should be considered for clinical trials.\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "在宫颈癌患者的一线化疗失败后，选择适当的治疗方案对缓解症状和延长生存时间非常重要。首先，建议积极加入缓和医疗团队，以提供全方位的支持。药物治疗方面，含有紫杉醇和铂类药物组合的化疗，可以考虑与或不与贝伐单抗（bevacizumab）联合使用，这是较为推荐的方案。\n\n目前，没有统一的标准二线化疗方案，因此对于这些患者来说，参与临床试验是值得考虑的选择。这可以为他们提供最新的治疗机会，并可能带来更好的临床结果。\n\n同时，针对个体情况调整治疗方案，并结合缓和疗法，可以帮助患者更好地管理疼痛及其他症状，从而提高生活质量。患者及其家属应与医生密切沟通，共同制定合适的治疗计划。"
}